# PACTO (NCT02767557)

> Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02767557
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Herlev Hospital
- Conditions: Unresectable Pancreatic Carcinoma
- Interventions: Tocilizumab; Gemcitabine; nab-Paclitaxel
- Enrollment: 147
- Primary outcome: Overall survival at 6 months

## Indexed commentary on PACTO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=pacto-nct02767557